01990nas a2200337   4500000000100000008004100001260001300042653001200055653003100067653002600098653002700124653002400151653001500175653001600190653001100206653001500217653000900232653002400241653002500265653001900290100001100309700001200320700000900332700000900341700001100350245014800361300001000509490000700519520111200526022001401638       1993                            d  c1993 Sep10aAnimals10aAntibodies, Anti-Idiotypic10aAntibodies, Bacterial10aAntibodies, Monoclonal10aAntigens, Bacterial10aBiomarkers10aGlycolipids10aHumans10aHybridomas10aMice10aMice, Inbred BALB C10aMycobacterium leprae10aTrisaccharides1 aWang D1 aJiang Z1 aMu J1 aLi M1 aWang B00a[Development of hybridomas secreting monoclonal anti-idiotypic antibodies that bear the internal image of the terminal trisaccharide of PGL-I].  a250-30 v243 a<p>Two hybridomas designated as F7B7 and F7B9 secreting monoclonal anti-idiotypic antibodies against terminal trisaccharide of PGL-I were developed by fusion of SP2/0 cells and spleen cells of BALB/c mouse immunized with mouse monoclonal anti-trisaccharide of PGL-I (MAb1-E10F1). To characterize the F7B7, the following results were obtained. First, F7B7 reacted with MAb1-E10F1 specifically. Secondly, the cross ELISA neutralizing tests gave positive results. The binding of anti-trisaccharide positive serum with trisaccharide (contained in semi-synthetic antigen, NT-O-BSA) was inhibited F7B7 and the degree of inhibition showed dose-dependent manner. The binding of anti-trisaccharide positive serum with F7B7 was inhibited by NT-O-BSA and the degree of inhibition also showed dose-dependent manner. It was concluded that the hybridoma F7B7 is able to secrete monoclonal anti-idiotypic antibodies that bear the internal image of trisaccharide of PGL-I. The potentials and advantages of monoclonal anti-idiotypic antibody F7B7 as surrogate antigen in the serodiagnosis of leprosy have been discussed.</p>  a0257-7712